PTPI (Petros Pharmaceuticals) Moat Score: 4/10 (As of Jun. 28, 2026)


What is Petros Pharmaceuticals Moat Score?

Petros Pharmaceuticals PTPI -1.07% Moat Score is 4 as of Jun. 28, 2026. Among 1,030 Drug Manufacturers companies, Petros Pharmaceuticals ranks better than 90.68% on this metric.

Petros Pharmaceuticals has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Petros Pharmaceuticals has Narrow Moat: Petros Pharmaceuticals has a discernible but modest moat due to its niche focus in pharmaceuticals. It holds some valuable intellectual property and benefits from regulatory barriers in the form of drug approvals, but faces competition and lacks strong brand strength.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Petros Pharmaceuticals might have Narrow Moat - Discernible but modest moat.

Petros Pharmaceuticals  (OTCPK:PTPI) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Petros Pharmaceuticals Moat Score Related Terms

PTPI vs GCAN, KOAN, PNXP: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Petros Pharmaceuticals Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Petros Pharmaceuticals's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Petros Pharmaceuticals (PTPI) has a Moat Score of 4 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Petros Pharmaceuticals ranks #96 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 9.3%.
Is Petros Pharmaceuticals' Moat Score too high?
Petros Pharmaceuticals' current Moat Score is 4. Based on the distribution chart, Petros Pharmaceuticals ranks #96 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Petros Pharmaceuticals' Moat Score compare to GCAN and KOAN?
According to the Drug Manufacturers industry distribution chart, Petros Pharmaceuticals ranks #96 out of 1030 companies for Moat Score. This places Petros Pharmaceuticals in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Petros Pharmaceuticals's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petros Pharmaceuticals stock overvalued right now?
Petros Pharmaceuticals (PTPI) has a current Moat Score of 4. The current Moat Score is 4. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Petros Pharmaceuticals (PTPI), the current Moat Score is 4 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Petros Pharmaceuticals Business Description

Address 1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. The Company is working towards the goal of becoming an innovator in the emerging self-care market, driving expanded access to key nonprescription pharmaceuticals as Over-the-Counter and nonprescription drug products with additional conditions for nonprescription use (ACNU Products) treatment options. Petros is pursuing the development of a proprietary integrated technology solutions platform containing two components: SaaS, designed to assist pharmaceutical companies in operationalizing and commercializing an Rx-to-OTC switch as an element in the development of an ACNU Product, and a potential Software as a Medical Device component, which guides the consumer in navigating appropriate self-selection or deselection.